Reuters logo
BRIEF-Coherus Biosciences says FDA acceptance of 351(K) biologics license application
October 6, 2016 / 10:06 PM / a year ago

BRIEF-Coherus Biosciences says FDA acceptance of 351(K) biologics license application

Oct 6 (Reuters) - Coherus Biosciences

* Announces FDA Acceptance Of 351(K) Biologics License Application to U.S. Food And Drug Administration for CHS-1701 (pegfilgrastim biosimilar candidate)

* Biosimilar User Fee Act (BSUFA) action date is June 9, 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below